Klaria Pharma Holding AB (SE:KLAR)
:KLAR
KLAR Stock Chart & Stats
kr0.61
>-kr0.01(-0.40%)
At close: 4:00 PM EST
kr0.61
>-kr0.01(-0.40%)
Day’s Range― - ―
52-Week Rangekr0.39 - kr1.37
Previous CloseN/A
Volume243.47K
Average Volume (3M)401.28K
Market Cap
kr230.73M
Enterprise Valuekr320.45M
Total Cash (Recent Filing)kr342.00K
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta2.35
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding245,976,150
10 Day Avg. Volume684,621
30 Day Avg. Volume401,283
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-31.79
Price to Sales (P/S)13.71
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr24.00M
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery TechnologyA proprietary mucoadhesive oral film platform is a durable competitive asset: it can lower barriers to entry, standardize formulation work across candidates, and create IP that supports repeated product development, licensing opportunities and longer-term differentiation versus generic routes.
Partnering/licensing StrategyAn explicit partnering and licensing approach reduces capital intensity and commercialization burden for a small R&D-focused firm. Over 2–6 months this structural model preserves cash, accelerates market reach via partners, and increases options to monetize the platform without scaling full commercial infrastructure.
Debt Reduced To Zero In 2025Elimination of reported debt in 2025 materially lowers fixed financing costs and interest exposure, improving near-term financial flexibility. Structurally this reduces creditor risk and the burden on operating cash flow, making equity or partnership funding more practical for development programs.
Bears Say
Negative Shareholders' EquityNegative equity is a structural impairment: it signals accumulated losses or dilution and constrains ability to raise debt, invites distressed financing terms, and increases insolvency risk. Over the medium term this reduces negotiating leverage with partners and heightens likelihood of dilutive capital raises to sustain operations.
Persistent Operating Cash BurnConsistent negative operating cash flow and a sharp increase to ~-35.0M in 2025 indicate the business cannot self-fund development. Structurally this creates recurring reliance on external financing, elevates dilution risk, and compresses runway unless partnerships or financing are secured on non-dilutive terms.
Ongoing Large Losses & Revenue VolatilityVery large negative margins and volatile, contracting revenue point to a persistent inability to scale profitable sales. Over several months this structural profitability gap undermines long-term sustainability, complicates partner/commercialization negotiations, and means R&D progress depends on securing external capital rather than internal cash generation.
KLAR FAQ
What was Klaria Pharma Holding AB’s price range in the past 12 months?
Klaria Pharma Holding AB lowest stock price was kr0.39 and its highest was kr1.37 in the past 12 months.
What is Klaria Pharma Holding AB’s market cap?
Klaria Pharma Holding AB’s market cap is kr230.73M.
When is Klaria Pharma Holding AB’s upcoming earnings report date?
Klaria Pharma Holding AB’s upcoming earnings report date is May 08, 2026 which is in 35 days.
How were Klaria Pharma Holding AB’s earnings last quarter?
Klaria Pharma Holding AB released its earnings results on Feb 20, 2026. The company reported -kr0.034 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.034.
Is Klaria Pharma Holding AB overvalued?
According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued.
Does Klaria Pharma Holding AB pay dividends?
Klaria Pharma Holding AB does not currently pay dividends.
What is Klaria Pharma Holding AB’s EPS estimate?
Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Klaria Pharma Holding AB have?
Klaria Pharma Holding AB has 245,976,150 shares outstanding.
What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?
Klaria Pharma Holding AB reported an EPS of -kr0.034 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.809%.
Which hedge fund is a major shareholder of Klaria Pharma Holding AB?
Currently, no hedge funds are holding shares in SE:KLAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.